# Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

> **NCT03114462** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 11 (estimated)

## Conditions studied

- Malignant Neoplasms of Respiratory and Intrathoracic Organs
- Squamous Cell Carcinoma of the Larynx

## Interventions

- **RADIATION:** Stereotactic Hypofractionated Radioablation
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT03114462
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-08-09
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 11 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03114462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03114462, "Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03114462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*